DE60322748D1 - Xanthinderivate als a2b-adenosinrezeptorantagonisten - Google Patents

Xanthinderivate als a2b-adenosinrezeptorantagonisten

Info

Publication number
DE60322748D1
DE60322748D1 DE60322748T DE60322748T DE60322748D1 DE 60322748 D1 DE60322748 D1 DE 60322748D1 DE 60322748 T DE60322748 T DE 60322748T DE 60322748 T DE60322748 T DE 60322748T DE 60322748 D1 DE60322748 D1 DE 60322748D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
adenosine receptor
xanthine derivatives
xanthine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322748T
Other languages
English (en)
Inventor
Rao Kalla
Thao Perry
Elfatih Elzein
Vaibhav Varkhedkar
Xiaofen Li
Prabha Ibrahim
Venkata Palle
Dengming Xiao
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Application granted granted Critical
Publication of DE60322748D1 publication Critical patent/DE60322748D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60322748T 2003-05-06 2003-05-06 Xanthinderivate als a2b-adenosinrezeptorantagonisten Expired - Lifetime DE60322748D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
DE60322748D1 true DE60322748D1 (de) 2008-09-18

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322748T Expired - Lifetime DE60322748D1 (de) 2003-05-06 2003-05-06 Xanthinderivate als a2b-adenosinrezeptorantagonisten

Country Status (16)

Country Link
EP (1) EP1622908B1 (de)
JP (1) JP2006515316A (de)
CN (1) CN100590125C (de)
AT (1) ATE403656T1 (de)
AU (1) AU2003249604B2 (de)
CA (1) CA2524778C (de)
CY (1) CY1108457T1 (de)
DE (1) DE60322748D1 (de)
DK (1) DK1622908T3 (de)
ES (1) ES2311759T3 (de)
HK (1) HK1092137A1 (de)
MX (1) MXPA05011860A (de)
NZ (1) NZ543416A (de)
PT (1) PT1622908E (de)
SI (1) SI1622908T1 (de)
WO (1) WO2004106337A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625881B2 (en) * 2005-06-16 2009-12-01 Gilead Palo Alto, Inc. Prodrugs of A2B adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
CN102438624B (zh) * 2009-03-13 2016-03-30 阿德维纳斯治疗私人有限公司 取代的稠合嘧啶化合物
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
WO2012035548A1 (en) 2010-09-13 2012-03-22 Advinus Therapeutics Private Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US9359359B2 (en) * 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP3389664A4 (de) * 2015-12-14 2020-01-08 Raze Therapeutics Inc. Koffeininhibitoren von mthfd2 und verwendungen dafür
WO2018204661A1 (en) * 2017-05-05 2018-11-08 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
MX2020009286A (es) * 2018-03-05 2020-12-11 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
DK0956855T3 (da) * 1998-04-24 2003-07-14 Leuven K U Res & Dev Immunhæmmende effekter af 8-substituerede xanthin-derivater
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
CA2451244C (en) * 2001-06-29 2012-01-17 Cv Therapeutics, Inc. Purine derivatives as a2b adenosine receptor antagonists
NZ532816A (en) * 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
US7205403B2 (en) * 2002-02-01 2007-04-17 King Pharmaceuticals Research And Development, Inc. 8-Heteroaryl xanthine adenosine A2B receptor antagonists

Also Published As

Publication number Publication date
JP2006515316A (ja) 2006-05-25
HK1092137A1 (en) 2007-02-02
EP1622908A1 (de) 2006-02-08
CN1771250A (zh) 2006-05-10
MXPA05011860A (es) 2006-02-17
NZ543416A (en) 2009-01-31
SI1622908T1 (sl) 2008-12-31
AU2003249604A1 (en) 2005-01-21
CA2524778A1 (en) 2004-12-09
ATE403656T1 (de) 2008-08-15
EP1622908B1 (de) 2008-08-06
CY1108457T1 (el) 2014-04-09
CA2524778C (en) 2013-01-29
CN100590125C (zh) 2010-02-17
DK1622908T3 (da) 2008-11-17
ES2311759T3 (es) 2009-02-16
AU2003249604B2 (en) 2011-06-30
PT1622908E (pt) 2008-11-14
WO2004106337A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
HK1092137A1 (en) Xanthine derivatives as a2b adenosine receptor antagonists
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
CY2017015I1 (el) ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS
WO2003042214A3 (en) A2b adenosine receptor antagonists
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
DE122012000043I1 (de) Pyrrolo[2,3-B]pyridinderivate als proteinkinaseinhibitoren.
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK2272517T3 (da) Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
DE60209251D1 (de) Adenosine a2a receptor antagonisten
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
DK1608653T3 (da) Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater
DE60333866D1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
ATE394402T1 (de) Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
IS7507A (is) Ný efnasambönd

Legal Events

Date Code Title Description
8364 No opposition during term of opposition